Breast implant illness in women with implant-based reconstruction after breast cancer

Abstract Background This study investigated the association between silicone breast implants and health symptoms (Breast Implant Illness (BII)) in women with implant-based breast reconstruction after breast cancer. While there is increasing evidence of an association with BII in cosmetic breast augmentation cases, for women with implant-based breast reconstruction this is unknown. Methods Retrospective cohort study of 254 women who underwent implant-based reconstruction after breast cancer and a control group of 487 women who underwent breast-conserving therapy or simple mastectomy. We linked Dutch Breast Implant Registry data (2015-2019) and general practice electronic health records data (2014-2022) to study the occurrence of thirteen BII-related health symptoms in general practice and the number of consultations for these symptoms one year before to three years after breast surgery. Results Over the three years following implantation, no significant differences in symptom occurrence were observed compared to both the year before implantation and the control group. Women with breast implants did not have more consultations compared to the control group during follow-up. However, there was an increased likelihood of multiple consultations in the first and second years post-implantation compared to before implantation (≥3 consultations first year OR = 2.10, p = 0.005; second year OR = 1.70, p = 0.048; ≥5 consultations first year OR = 2.57, p = 0.02). Conclusions This study found no evidence for BII in women with implant-based reconstruction after breast cancer. Despite certain limitations in examining BII in this specific patient group, these findings add valuable information to the decision-making process of breast cancer patients considering reconstructive options. Key messages • This is the first study on BII that focused solely on women with breast implants for reconstruction after breast cancer. • No evidence of BII was found in this patient group.